MedTrace Logo

Paricalcitol on Albuminuria, Inflammation and Fibrosis on Proteinuric Chronic Renal Diseases (PALIFE Study)

NCT01820078 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 127

Last updated 2013-11-28

No results posted yet for this study

Summary

The purpose of this study is to estimate the differences between albuminuria values determined as Urine Albumin-to-Creatinine Ratio (UACR)(log transformed) from baseline to last observation caused by paricalcitol between the group of control and group of treatment.

Conditions

  • Chronic Kidney Disease, Unspecified

Interventions

DRUG

Experimental arm

Oral paricalcitol, 1 ug/day, plus daily treatment. 6 months (all study)

OTHER

Comparator Arm

Daily treatment is not define by protocol, because daily treatment in CKD is highly variable and includes salt and/or blood pressure regulation, angiotensine system stoppers, controlled diet, etc.

Sponsors & Collaborators

  • Effice Servicios Para la Investigacion S.L.

    collaborator INDUSTRY

  • Fundación Renal Iñigo Alvarez De Toledo

    lead OTHER

Principal Investigators

  • Jesús Egido de los Ríos, MD · Fundación Renal Iñigo Alvarez De Toledo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-09-30
Completion
2013-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01820078 on ClinicalTrials.gov